Table 3.
Respiratory therapies
| Pre-AOC implementation | Post-AOC implementation | P value* | |
|---|---|---|---|
| High-frequency oscillation, n (%) | 56 (19.1) | 51 (17.3) | 0.57 |
| Inhaled nitric oxide, n (%) | 31 (10.6) | 32 (10.5) | 0.92 |
| Dexamethasone, n (%) | 27 (9.2) | 29 (9.8) | 0.80 |
| Surfactant, n (%) | 164 (56.0) | 147 (49.8) | 0.14 |
| Via intubation, n (%) | 131 (44.7) | 76 (25.8) | < 0.001 |
| Via minimally invasive technique, n (%) | 33 (11.3) | 71 (24.1) | |
| Invasive ventilation days, mean (SD) | 6.4 (10.1) | 4.7 (8.3) | 0.029 |
| CPAP days, mean (SD) | 10.8 (11.7) | 13.9 (15.2) | 0.006 |
| HFNC days, mean (SD) | 2.3 (5.4) | 5.8 (8.1) | < 0.001 |
| Low flow days, mean (SD) | 1.5 (3.4) | 1.5 (3.2) | 0.86 |
| Supplemental oxygen days, mean (SD) | 8.0 (13.5) | 11.3 (16.9) | 0.008 |
| Average inspired oxygen | |||
| During first week, mean (SD) | 25.2 (10.2) | 24.8 (8.8) | 0.58 |
| During entire admittance, mean (SD) | 25.7 (9.8) | 25.7 (9.1) | 0.93 |
CPAP continuous positive airway pressure, HFNC high-flow nasal cannula; Average inspired oxygen (expressed as %) while on respiratory support
*Statistical analysis with independent T-test or χ2 test as appropriate